Rx Partnership receives Amerigroup grant to provide Virginians with medication access

NewsGuard 100/100 Score

The Amerigroup Foundation today announced that it has provided a grant of $10,000 to the Rx Partnership in Richmond, Virginia. The grant will be used to support increased access to medications in four free clinics in Virginia.

The Rx Partnership is an organization that works to provide uninsured Virginians with access to medication through community-based clinics by serving as a broker to access and distribute free bulk prescription medications to 20 affiliated community-based clinics.  Rx Partnership's unique bulk replacement method results in a streamlined, efficient and cost effective process that delivers more drugs to a greater number of patients in need. More than $50 million in free medication has been provided to over 35,500 uninsured Virginians since the program began in 2002.

The first $2,500 of the $10,000 grant provided to Rx Partnership supports the Augusta Regional Free Clinic in Fishersville, Virginia. "Rx Partnership is pleased to add Amerigroup as a key partner in 2011," said Amy Yarcich, executive director of RxP. "Through their generous contribution, Amerigroup is helping to support the delivery of medication to uninsured patients at Augusta Regional Free Clinic and 19 other free clinics and community health centers around the state who rely on Rx Partnership to help their most vulnerable patients receive the vital medication they need to treat a variety of chronic conditions like diabetes, hypertension and asthma." 

Senator Emmett Hanger (R-Augusta) added, "The Augusta Regional Free Clinic is such a key player in our community by providing healthcare, dental and pharmaceutical services for the uninsured. In a time when state and local governments are trying to do more with less, Free Clinics help provide that safety net to reach our community members in need. This grant demonstrates the commitment of the staff and medical providers here and I am pleased their efforts and dedication are being recognized."  

"One of the most significant benefits for patients of the Augusta Regional Free Clinic is our ability to offer free medicine on site," said Margaret Hersh, executive director of the Augusta Regional Free Clinic. "Without the medication assistance from Rx Partnership our 1,600 patients would have difficulty obtaining the more than 30,000 prescriptions provided at the clinic and valued at over $2.4 million that are distributed to them. These medications help our patients maintain quality of life and prevent needless suffering. The partnership between Rx Partnership and Amerigroup will ensure that underserved patients in our community and across Virginia will continue to have access to medications that impact the most basic human needs of health and well-being."

"The Rx Partnership works to focus attention on the access of medication for the uninsured," said John E. Littel, chairman of the Amerigroup Foundation. "We are so pleased the Foundation was able to play a part in supporting this worthy cause."

The three remaining grants will support medication delivery to selected free clinics in Virginia and will be awarded quarterly throughout the remainder of 2011.

SOURCE Amerigroup Foundation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show